Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

Laboratory Evolution of Virus-likE pRotein cAGes for Eukaryotic mRNA delivery

Descrizione del progetto

Gabbie batteriche per la somministrazione di mRNA nelle cellule

La terapia genica rappresenta un approccio promettente per trattare numerose malattie genetiche, ma richiede la somministrazione di acidi nucleici nelle cellule, un compito che si è rivelato piuttosto impegnativo. Il progetto LEVERAGE mRNA, finanziato dall’UE, propone lo sviluppo di contenitori cavi composti da proteine per somministrare molecole di RNA, imitando la struttura dei virus. I ricercatori del progetto impiegheranno la lumazina sintasi, una proteina batterica nota per formare nanocompartimenti simmetrici in grado di smantellare le cellule interne dei mammiferi e rilasciare nel citosol le molecole di RNA incapsulate. L’approccio di LEVERAGE mRNA fornisce una strategia promettente per la somministrazione di molecole di mRNA allo scopo di sostituire proteine mancanti o disfunzionali, come nelle terapie di sostituzione enzimatica, con benefici evidenti per la salute umana.

Obiettivo

Nucleic acids are promising candidates for treating disease by stimulating, inhibiting, or replacing other nucleic acids or proteins inside of eukaryotic cells—a process known as “gene therapy.” However, methods to efficiently and safely deliver genes into cells are still lacking. The problem is that nucleic acids are not cell permeant and degrade before reaching the cytosol. One way to transport oligonucleotides into cells is by packaging them into hollow containers made of proteins, a method that has been successfully hijacked by viruses for a long time.

Here, we propose to design and engineer an artificial proteinaceous container that (1) selectively encapsulates ribonucleic acids (RNAs) using a known RNA recognition tag and (2) delivers this RNA into the cytosol of mammalian cells. Protein engineering, which embodies both rational design and computational modeling, will be used to create the starting design of this artificial protein container. The initial design will be based on the protein lumazine synthase from the bacterial organism Aquifex aeolicus (AaLS), which forms small but highly symmetrical nanocompartments in bacteria and is very tolerant to genetic changes. To optimize this design, we will use directed evolution to induce an artificial selection pressure on a large population of distinct capsid variants, allowing us to obtain only the best-performing capsid variants: those that can enter and disassemble selectively inside of mammalian cells, thereby releasing the enclosed RNA molecules into the cytosol. New AaLS containers will be thoroughly characterized using cutting-edge technologies, such next-generation sequencing and cryo-electron microscopy.

The ultimate goal of LEVERAGE mRNA is to use the designed and evolved capsids to deliver messenger RNAs (mRNAs) into cells that encode missing or dysfunctional proteins, for example in enzyme replacement therapies. If successful, this action will have lasting positive impacts on human health.

Campo scientifico (EuroSciVoc)

Programma(i)

Argomento(i)

Meccanismo di finanziamento

MSCA-IF-EF-ST - Standard EF

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) H2020-MSCA-IF-2018

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH
Contributo netto dell'UE
€ 191 149,44
Indirizzo
Raemistrasse 101
8092 Zuerich
Svizzera
Regione
Schweiz/Suisse/Svizzera Zürich Zürich
Tipo di attività
Higher or Secondary Education Establishments
Collegamenti
Costo totale
€ 191 149,44